 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Jul 03, 2023 |
| Title |
CTLA-4 pathway is instrumental in Giant Cell Arteritis |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
BACKGROUND: Giant Cell Arteritis (GCA) causes severe inflammation of the aorta and its branches and is characterized by intense effector T cells infiltration. The roles that immune checkpoints play in pathogenesis of GCA are still unclear.Our aim was to study the immune checkpoints interplay in GCA. METHODS: First, we used VigiBase, the WHO international pharmacovigilance database, to evaluate the relationship between GCA occurrence and immune checkpoint inhibitors (ICI) treatments. We then further dissected the role of ICI in the pathogenesis of GCA, using immunohistochemistry, immunofluorescence, transcriptomics and flow cytometry on peripheral blood mononuclear cells (PBMCs) and aortic tissues of GCA patients and appropriated controls.
RESULTS: Using VigiBase, we identified GCA as a significant immune related adverse event associated with anti-CTLA-4 (Cytotoxic T-lymphocyte-associated-protein-4) but not anti-PD-1/PD-L1 treatment. We further dissected a critical role for CTLA-4 pathway in GCA by identification of the dysregulation of CTLA-4-derived gene pathways and proteins in CD4+ T cells (and specifically Tregs) present in blood and aorta of GCA patients versus controls. While Tregs were less abundant and activated/suppressive in blood and aorta of GCA versus controls, they still specifically upregulated CTLA-4. Activated and proliferating CTLA-4+ Ki-67+ Tregs from GCA were more sensitive to anti-CTLA-4 (Ipilimumab)-mediated in vitro depletion versus controls. CONCLUSIONS: We highlighted the instrumental role of CTLA-4 immune checkpoint in GCA which provides a strong rationale for targeting this pathway.
|
| |
|
| Overall design |
We performed Illumina HumanHT-12 V4 beadarray assay on MACS-sorted CD4+ T cells extracted from PBMCs obtained from whole blood of 15 healthy donors (HD) and 19 patients with active Giant Cell Arteritis (aGCA).
|
| |
|
| Contributor(s) |
Régnier P, Le Joncour A, Maciejewski-Duval A, Darrasse-Jèze G, Dolladille C, Meijers WC, Bastarache L, Fouret P, Bruneval P, Arbaretaz F, Sayetta C, Márquez A, Rosenzwajg M, Klatzmann D, Cacoub P, Moslehi JJ, Salem J, Saadoun D |
| Citation(s) |
37435729 |
| Submission date |
Jul 03, 2023 |
| Last update date |
Jul 17, 2023 |
| Contact name |
Paul Régnier |
| E-mail(s) |
paul.jb.regnier@gmail.com
|
| Organization name |
AP-HP
|
| Street address |
83 boulevard de l'hôpital
|
| City |
Paris |
| ZIP/Postal code |
75013 |
| Country |
France |
| |
|
| Platforms (1) |
| GPL10558 |
Illumina HumanHT-12 V4.0 expression beadchip |
|
| Samples (34)
|
|
| Relations |
| BioProject |
PRJNA990713 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE236367_RAW.tar |
80.7 Mb |
(http)(custom) |
TAR (of IDAT) |
| GSE236367_non-normalized.txt.gz |
12.4 Mb |
(ftp)(http) |
TXT |
| GSE236367_normalized.txt.gz |
11.9 Mb |
(ftp)(http) |
TXT |
| Processed data included within Sample table |
| Processed data are available on Series record |
|
|
|
|
 |
Less...
More...